ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
June 14, 2023 08:31 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
May 15, 2023 16:05 ET
|
ReShape Lifesciences Inc
Achieved Continued Improvement in Operational Effectiveness With First Quarter 2023 Operating Expenses Down 42.9% Compared to the First Quarter of 2022 Executing a Plan For Growth and Profitability...
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
May 11, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it...
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
April 27, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will...
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
April 25, 2023 16:05 ET
|
ReShape Lifesciences Inc
Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of...
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
April 20, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
April 11, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the...
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
March 28, 2023 21:50 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that...
ReShape Lifesciences Announces Formation of International Scientific Advisory Board
March 23, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the...
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
March 22, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that...